Polynovo Valuation Multiples

Polynovo Overview

About Polynovo

Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita’s RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.

Founded

1998

HQ

Employees

301

Website

polynovo.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $100M

EBITDA: $8M

EV

$439M

Valuation Multiples

Multiples.vc

Start free trial

Polynovo Financials

Polynovo reported last 12-month revenue of $100M and EBITDA of $8M.

In the same LTM period, Polynovo generated $92M in gross profit, $8M in EBITDA, and $5M in net income.

Polynovo P&L

In the most recent fiscal year, Polynovo reported revenue of $88M and EBITDA of $7M.

Polynovo expects next 12-month revenue of XXX and NTM EBITDA of XXX

Polynovo Stock Performance

Polynovo has current market cap of $447M, and enterprise value of $439M.

Polynovo's stock price is $0.65.

Polynovo Valuation Multiples

Polynovo trades at 4.4x EV/Revenue multiple, and 55.9x EV/EBITDA.

Polynovo Financial Valuation Multiples

As of April 8, 2026, Polynovo has market cap of $447M and EV of $439M.

Equity research analysts estimate Polynovo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Polynovo has a P/E ratio of 88.5x.

Polynovo Margins & Growth Rates

Polynovo's revenue in the last 12 month grew by 22%.

Polynovo's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.

Polynovo's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Polynovo's rule of X is 63% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Polynovo Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Polynovo M&A Activity

Polynovo acquired XXX companies to date.

Last acquisition by Polynovo was on XXXXXXXX, XXXXX. Polynovo acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Polynovo Investment Activity

Polynovo invested in XXX companies to date.

Polynovo made its latest investment on XXXXXXXX, XXXXX. Polynovo invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).